The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
Recruiting at 2 trial locations
SA
Overseen byScott Aaronson, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Sheppard Pratt Health System
No Placebo Group
Prior Safety Data
Approved in 2 Jurisdictions
Trial Summary
What is the purpose of this trial?
This trial is testing whether psilocybin, a compound from 'magic mushrooms,' can help improve depression in adults with Bipolar II Disorder. The idea is that psilocybin changes brain chemistry to improve mood. Psilocybin has shown promise as a treatment for major depressive disorder and was recognized by the FDA in 2019.
Research Team
SA
Scott Aaronson, MD
Principal Investigator
Sheppard Pratt Health System
Eligibility Criteria
Inclusion Criteria
You have been diagnosed with depression related to Type 2 Bipolar Disorder (BP-II).
Exclusion Criteria
You have other medical conditions in addition to the one being studied.
Treatment Details
Interventions
- Psilocybin (Psychedelic)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: PsilocybinExperimental Treatment1 Intervention
25mg of Psilocybin
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sheppard Pratt Health System
Lead Sponsor
Trials
23
Recruited
7,800+
COMPASS Pathways
Industry Sponsor
Trials
15
Recruited
1,400+